Recent Publications

  1. Kochhar S,Izurieta HS, Chandler RE, Hacker A, Chen RT, Levitan B. Benefit-Risk Assessment of Vaccines. Vaccine 2023, https://doi.org/10.1016/j.vaccine.2023.07.041
  2. Levitan B, Hadler SC, Hurst W, Izurieta HS, Smith ER, Baker NL, Bauchau V, Chandler R, Chen RT, Craig D, King J, Pitisuttithum P, Strauss W, Tomczyk S, Zafack J, Kochhar S. The Brighton collaboration standardized module for vaccine benefit-risk assessment. Vaccine. 2023, S0264-410X(23)01109-X. doi: 10.1016/j.vaccine.2023.09.039
  3. Kochhar S, Okomo U, Nkereuwem O, Shaum A, Gidudu JF, Bittaye M, Fofana S, Marena M, Kaira MJ, Kampmann B, Longley AT. Establishing Vaccine Pregnancy Registries and Active Surveillance Studies in Low-and Middle-Income Countries: Experience from an Observational Cohort Surveillance Project in The Gambia. 2023;41(44):6453-6455. doi: 10.1016/j.vaccine.2023.09.038
  4. GBD 2021 Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Accepted for publication by The Lancet, 2024
  5. GBD 2021 Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Accepted for publication by The Lancet Neurology, 2024
  6. GBD 2021 Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Accepted for publication by The Lancet, 2024
  7. Fleming JA, Baral R, Higgins D, Khan S, Kochhar S, Li Y, Ortiz JR, Cherian T, Feikin D, Jit M, Karron RA, Limaye RJ, Marshall C, Munywoki PK, Nair H, Newhouse LC, Nyawanda BO, Pecenka C, Regan K, Srikantiah P, Wittenauer R, Zar HJ, Sparrow E. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies. Vaccine. 2023;41 Suppl 2:S7-S40. doi: 10.1016/j.vaccine.2022.09.081
  8. GBD 2021 Collaborators. Global, regional, and national stillbirths by gestational age for 204 countries and territories from 1990 to 2021. Accepted for publication in The Lancet, 2024
  9. März J, Kochhar S, Biller-Andorno N, Reis A, Lewis R, Schaefer O. WHO guidance on the global mpox outbreak response: ethics issues and considerations. Accepted for publication in Vaccine, 2024
  10. GBD 2021 Collaborators. Acute versus chronic care needs: An analysis of the Global Burden of Disease Study 2019. Accepted for publication by Nature Communications, 2024
  11. GBD 2021 Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021. Accepted for publication by the Lancet, 2024
  12. Kochhar S, Barreira D, Beattie P, Cavaleri M, Cravioto A, Frick MW, Ginsberg AM, Hudson I, Kaslow DC, Kurtz S, Lienhardt C, Madhi SA, Morgan C, Momeni Y, Patel D, Rees H, Rogalski-Salter T, Schmidt A, Semete-Makokotlela B, Voss G, White RG, Zignol M, Giersing B. Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test. Vaccine, 2022: 2022: S0264-410X (21)01395-5. doi: 10.1016/j.vaccine.2021.10.062
  13. Wilder-Smith A, Kochhar S. Safety and reactogenicity of second booster doses for mRNA vaccines. Lancet Respir Med. 2022: sS2213-2600(22)00451-9. doi: 10.1016/S2213-2600(22)00451-9. PMID: 36410365
  14. Gold MS, Amarasinghe A, Greenhawt M, Kelso JM, Kochhar S, Yu-Hor Thong B, Top KA, Turner PJ, Worm M, Law B. Anaphylaxis: revision of the Brighton Collaboration case definition. Vaccine. 2023;41(15):2605-2614. doi: 10.1016/j.vaccine.2022.11.027
  15. Heininger U, Buttery J, Kochhar S. Harmonized case definitions for endpoints in vaccine efficacy trials are needed. Vaccine. 2023;41(27):3947. doi: 10.1016/j.vaccine.2022.11.070
  16. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221-2248. doi: 10.1016/S0140-6736(22)02185-7
  17. GBD 2019 Collaborators. Structural racism engendered by historical Jim Crow laws in the US is associated with racial health disparities in tuberculosis disease burden: an analysis of the Global Burden of Disease (GBD) and Risk Factors data, 1990 to 2019. Accepted for publication by The Lancet, 2024
  18. GBD 2019 Collaborators. Gender inequality in oral-rehydration solution coverage in low, middle, and low-middle socio-demographic index countries. Accepted for publication in The Lancet Global Health, 2024
  19. Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus. Vaccine. 2022;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006.
  20. Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, O’Brien KL, Hombach J, Wilder-Smith A. Response to additional COVID-19 vaccine doses in immunocompromised persons: a rapid review. Lancet Glob Health. 2022;10(3):e326-e328. doi: 10.1016/S2214-109X(21)00593-3
  21. McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S, MacDonald N, Madhi SA, Mohsni E, Mulholland K, Neuzil KM, Nohynek H, Olayinka F, Pitisuttithum P, Pollard AJ, Cravioto A.  COVID-19 vaccine strategies must focus on severe disease and global equity. Lancet. 2022:399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X
  22. Parker EPK, Desai S, Marti M, O’Brien KL, Kaslow DC, Kochhar S, Olayinka F, Cravioto A, Nohynek H, Hombach J, Wilder-Smith A Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?. Lancet Infect Dis. 2022, S1473-3s099(22)00178-5. doi: 10.1016/S1473-3099(22)00178-5
  23. Faden R, Cravioto A, Hombach J, Kaslow DC, Kochhar S, Nohynek H, Wilder-Smith A, Crane MA, Omer SB. Who to vaccinate first? A peek at decision-making in a pandemic. Nature. 2022 Jul;607(7918):235-238. doi: 10.1038/d41586-022-01899-2. PMID: 35821419
  24. Singh JA, Kochhar S, Wolff J, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho C, Moon S, Shamsi-Gooshki E, Touré A, Thomé B, Smith MJ, Upshur REG.  WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations. Vaccine. 2022;40(14):2140-2149. doi: 10.1016/j.vaccine.2022.02.038
  25. GBD 2019 LRI Collaborators. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022;22(11):1626-1647. doi: 10.1016/S1473-3099(22)00510-2
  26. GBD 2019 Human Resources for Health Collaborators. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;399(10341):2129-2154. doi: 10.1016/S0140-6736(22)00532-3
  27. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with selected bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. 2022;400(10369):2221-2248. doi: 10.1016/S0140-6736(22)02185-7
  28. Top KA, Chen RT, Levy O, Ozonoff A, Carleton B, Crawford NW, Creech CB, Kochhar S, Poland GA, Gutu K, Cutland CL.  Advancing the Science of Vaccine Safety during the COVID-19 Pandemic and Beyond: Launching an International Network of Special Immunization Services. Clin Infect Dis. 2022;75(Suppl 1):S11-S17. doi: 10.1093/cid/ciac407
  29. Kochhar S, Dubé E, Graham J, Jee Y, Memish ZA, Menning L, Nohynek H, Salmon D, Top KA, MacDonald NE. COVID-19 Vaccine Safety Questions and Answers for Healthcare Providers (CONSIDER). Vaccine. 2021;39(18):2504-2505. doi: 10.1016/j.vaccine.2021.03.060
  30. Ortiz JR, Yu SL, Driscoll AJ, Williams SR, Robertson J, Hsu JS, Chen WH, Biellik RJ, Sow S, Kochhar S, Neuzil KM.  The operational feasibility of vaccination programs targeting influenza risk groups in the WHO African and South-East Asian Regions. Clin Infect Dis. 2022;74(2):227-236. doi: 10.1093/cid/ciab393
  31. Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho CW, Kochhar S, Schaefer GO, Shamsi-Gooshki E, Singh JA, Smith MJ, Wolff J. Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability.  Lancet. 2022 Jan 29;399(10323):487-494. doi: 10.1016/S0140-6736(21)02344-8
  32. Heidari S, Durrheim DN, Faden R, Kochhar S, MacDonald N, Olayinka F, Goodman TS. Time for action: towards an intersectional gender approach to COVID-19 vaccine development and deployment that leaves no one behind. BMJ Glob Health. 2021;6(8):e006854. doi: 10.1136/bmjgh-2021-006854
  33. Wolff J, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho CWL, Kochhar S, Moon S, Schaefer OG, Shamsi-Gooshki E, Singh JA, Smith MJ, Thomé B, Touré A, Upshar R. Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines. BMJ Global Health 2021, 6:e005912. http://dx.doi.org/10.1136/bmjgh-2021-005912
  34. Local Burden of Disease HIV Collaborators.Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. Lancet HIV. 2021;8(6):e363-e375. doi: 10.1016/S2352-3018(21)00051-5
  35. GBD 2019 HIV Collaborators. Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV. 2021;8(10):e633-e651. doi: 10.1016/S2352-3018(21)00152-1
  36. Singh J A, Kochhar S, Wolff J. Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group. Nat Med. 2021;27(4):569-570. doi: 10.1038/s41591-021-01299-5.
  37. Kochhar S, Salmon D. Planning for COVID-19 Vaccines Safety surveillance. 2020;38(40):6194-6198. doi: 10.1016/j.vaccine.2020.07.013
  38. Graepel KW, Kochhar S, Clayton EW, Edwards KE. Balancing Expediency and Scientific Rigor in SARS-CoV-2 Vaccine Development. J Infect Dis. pii: jiaa234. doi: 10.1093/infdis/jiaa234
  39. Edwards KM, Kochhar S. Ethics of Conducting Clinical Research in an Outbreak Setting. Annu Rev Virol. 2020;7(1):475-494. doi: 10.1146/annurev-virology-013120-013123
  40. Bar-Zeev N, Kochhar S. Expecting the unexpected with COVID-19 vaccines. Lancet Infect Dis. 2021 Feb;21(2):150-151. doi: 10.1016/S1473-3099(20)30870-7
  41. LBD Triple Burden Collaborators. The overlapping burden of the three leading causes of disability and death in sub-Saharan African children. Nat Commun. 2022;13(1):7457. doi: 10.1038/s41467-022-34240-6
  42. Duszynski KM, Stark JH, Cohet C, Huang WT, Shin JY, Lai EC, Man KKC, Choi NK, Khromava A, Kimura T, Huang K, Watcharathanakij S, Kochhar S, Chen RT, Pratt NL. Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety. Pharmacoepidemiol Drug Saf. 2021;30(7):843-857. doi: 10.1002/pds.5214
  43. Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT. The Brighton Collaboration Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Protein Vaccines. 2020;38(35):5734-5739. doi: 10.1016/j.vaccine.2020.06.044
  44. Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT. The Brighton Collaboration Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Inactivated viral vector vaccines. 2020;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028
  45. Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S. The Brighton Collaboration standardized template for collection of key information for Benefit-Risk Assessment of Viral Vector Vaccines. Vaccine, 2020. 2020; S0264-410X(20)31030-6. doi:10.1016/j.vaccine.2020.08.009
  46. Kim D, Robertson JS, Excler JL, Condit RC, Fast PE, Gurwith M, Pavlakis G, Monath TP, Smith J, Wood D, Smith ER, Chen RT, Kochhar S. The Brighton Collaboration Standardized Template for Collection of Key Information for Risk/Benefit Assessment of Nucleic Acid (RNA and DNA) Vaccines. Vaccine. 2020;38(34):5556-5561. doi: 10.1016/j.vaccine.2020.06.017
  47. Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. 2020;38(49):7702-7707. doi: 10.1016/j.vaccine.2020.09.042.
  48. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 2020; 396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2
  49. Chen R, Kochhar S, Condit RC. The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). 2021 May 21;39(22):3050-3052. doi: 10.1016/j.vaccine.2020.10.072
  50. Steer PJ, Russell AB, Kochhar S, Cox P, Plumb J, Gopal Rao G.Group B streptococcal disease in the mother and newborn – a review.Eur J Obstet Gynecol Reprod Biol. 2020; 252:526-533. doi: 10.1016/j.ejogrb.2020.06.024
  51. Eckert LO, Jones CE, Kachikis A, Bardají A, Silva FTD, Absalon J, Rouse CE, Khalil A, Cutland CL, Kochhar S, Munoz FM.Obstetrics Risk Assessment: Evaluation of Selection Criteria for Vaccine Research Studies in Pregnant Women. Vaccine. 2020, 38 (29): 4542-4547. https://doi.org/10.1016/j.vaccine.2020.05.022
  52. Local Burden of Disease WaSH Collaborators. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. The Lancet Global Health. 2020, 8(9), e1162-e1185. https://doi.org/10.1016/S2214-109X(20)30278-3
  53. Nkereuwem OO, Kochhar S, Wariri O, Johm P, Ceesay A, Kinteh M, Kampmann B.  The use of a speaking book to enhance vaccine knowledge among caregivers in The Gambia: A study using qualitative and quantitative methods. BMJ Open 2021;11:doi: 10.1136/bmjopen-2020-040507
  54. Local Burden of Disease Diarrhoea Collaborators. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. Lancet Glob Health. 2020;8(8):e1038-e1060. doi: 10.1016/S2214-109X(20)30230-8
  55. LBD Child Growth Failure Collaborators. Mapping child growth failure across low- and middle-income countries. Nature. 2020; 577(7789):231-234. doi: 10.1038/s41586-019-1878-8
  56. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2
  57. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 2020 Oct 17;396(10258):1250-1284. doi: 10.1016/S0140-6736(20)30750-9.
  58. Kochhar S, Edwards KM, Ropero Alvarez AM, Moro PL, Ortiz JR. Introduction of New Vaccines for Immunization in Pregnancy- Programmatic, Regulatory and Safety Considerations. Vaccine 2019, 37:25, 3267-3277. https://doi.org/10.1016/j.vaccine.2019.04.075
  59. Kochhar S, Knoppers B, Gamble C, Chant A, Koplan J, Humphreys GS. Clinical Trial Data Sharing: Here’s the Challenge. BMJ Open. 2019; 9(8):e032334. doi: 10.1136/bmjopen-2019-032334.
  60. GBD 2017 Diarrhoeal Disease Collaborators. Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019. pii: S1473-3099(19)30401-3. doi: 10.1016/S1473-3099(19)30401-3
  61. GBD 2017 Lower Respiratory Infections Collaborators. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019, pii: S1473-3099(19)30410-4. doi: 10.1016/S1473-3099(19)30410
  62. Villagomez AN, Muñoz FM, Peterson RL, Colbert AM, Gladstone M, MacDonald B, Wilson R, Fairlie L, Gerner GJ, Patterson J, Boghossian NS, Burton VJ, Cortés M, Katikaneni LD, Larson JCG, Angulo AS, Joshi J, Nesin M, Padula MA, Kochhar S, Connery AK. Neurodevelopmental delay: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019; 37(52):7623-7641. doi: 10.1016/j.vaccine.2019.05.027.
  63. Kachikis A, Eckert LO, Walker C, Bardají A, Varricchio F, Lipkind HS, Diouf K, Huang WT, Mataya R, Bittaye M, Cutland C, Boghossian NS, Mallett Moore T, McCall R, King J, Mundle S, Munoz FM, Rouse C, Gravett M, Katikaneni L, Ault K, Klein NP, Roberts DJ, Kochhar S, Chescheir N. Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019; 37(52):7610-7622. doi: 10.1016/j.vaccine.2019.05.030.
  64. Pellegrin S, Munoz FM, Padula M, Heath PT, Meller L, Top K, Wilmshurst J, Wiznitzer M, Das MK, Hahn CD, Kucuku M, Oleske J, Vinayan KP, Yozawitz E, Aneja S, Bhat N, Boylan G, Sesay S, Shrestha A, Soul JS, Tagbo B, Joshi J, Soe A, Maltezou HC, Gidudu J, Kochhar S, Pressler RM. Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019;37(52):7596-7609. doi: 10.1016/j.vaccine.2019.05.031.
  65. Kochhar S, Clarke E, Izu A, Emmanuel Kekane-Mochwari K, Cutland CL. Immunization in Pregnancy Safety Surveillance in Low- and Middle-Income Countries- Field Performance and Validation of Novel Case Definitions. Vaccine 2019. 37:22, 2967-2974. https://doi.org/10.1016/j.vaccine.2019.03.074
  66. Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO.Pregnant Women and Vaccines against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, and Response. Vaccine 2019. pii: S0264-410X(19)30045-3. doi: 10.1016/j.vaccine.2019.01.011
  67. Kochhar S, Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT. Defining the interval for monitoring potential adverse events following immunisation (AEFIs) after receipt of live viral vectored vaccines.
    Vaccine 37 (38    ), 5796-5802, 2019. Doi: https://doi.org/10.1016/j.vaccine.2018.08.085
  68. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 Study. Lancet HIV. pii: S2352-3018(19)30196-1. doi: 10.1016/S2352-3018(19)30196-1.
  69. Rouse CE, Eckert LO, Muñoz FM, Stringer JSA, Kochhar S, Bartlett L, Sanicas M, Dudley DJ, Harper DM, Bittaye M, Meller L, Jehan F, Maltezou HC, Šubelj M, Bardaji A, Kachikis A, Beigi R, Gravett MG. Postpartum Endometritis and Infection following Incomplete or Complete Abortion. Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Maternal Immunization Safety Data. Vaccine, 2019, 37(52):7585-7595. doi: 1016/j.vaccine.2019.09.101
  70. GBD 2017 Child and Adolescent Health Collaborators. Diseases, Injuries, and Risk Factors in Child and Adolescent Health, 1990 to 2017 Findings from the Global Burden of Diseases, Injuries, and Risk Factors 2017 Study. JAMA Pediatr.2019: e190337. doi: 10.1001/jamapediatrics.2019.0337
  71. GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2018; 392(10159):1995-2051. doi: 10.1016/S0140-6736(18)32278-5.
  72. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalizations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019 Jan;7(1):69-89. doi: 10.1016/S2213-2600(18)30496-X. Epub 2018 Dec 12.
  73. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2018; 392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3.
  74. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6.
  75. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, 2018, 18(11): 1191-1210, 2018. doi: 10.1016/S1473-3099(18)30310-4
  76. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1684-1735. doi: 10.1016/S0140-6736(18)31891-9
  77. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5.
  78. GBD 2017 Causes of Death Collaborators.Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7.
  79. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7
  80. Rouse CE, Kachikis A, Eckert LO, Munoz FM, Kochhar S, Bartlett LA, Gravett MG. Postpartum endometritis: development of a maternal outcome definition for international immunization research through the GAIA project. American Journal of Obstetrics and Gynecology. December 2018, 219: 6, 654- 655. DOI: https://doi.org/10.1016/j.ajog.2018.10.065
  81. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018 Dec;18(12):1329-1349. doi: 10.1016/S1473-3099(18)30625-X.
  82. Stark JH, Wool E, Tran L, Robinson E, Chemelski M, Weibel D, Huang WT, Kochhar S, Hardy JR, Bailey S, Galiwango E, Kajungu D. Assessing feasibility of resources at health facilities in Uganda to diagnose pregnancy and neonatal outcomes.Int Health. 2019 Mar 1;11(2):128-135. doi: 10.1093/inthealth/ihy066.
  83. Ndaya-Oloo P, Pitisuttithum P, Tornieporth NG, Desgrandchamps D, Munoz FM, Kochhar S, Buttery J, Bauwens J, Bonhoeffer J. Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. J Clin Pharmacol. 2018;58 Suppl 10:S123-S139. doi: 10.1002/jcph.1140.
  84. GBD 2016 Lower Respiratory Infections Collaborators.Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018. pii: S1473-3099(18)30310-4. doi: 10.1016/S1473-3099(18)30310-4
  85. GBD 2016 Diarrhoeal Disease Collaborators.Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018. pii: S1473-3099(18)30362-1. doi: 10.1016/S1473-3099(18)30362-1
  86. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018; 392(10152):1015-1035. doi: 10.1016/S0140-6736(18)31310-2
  87. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2
  88. Kochhar S, Bonhoeffer J, Jones CE, Muñoz FM, Honrado A, Bauwens J, Sobanjo-Ter Meulen A, Hirschfeld S. Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations.  Vaccine. 2017;35(48 Pt A):6575-6581. doi:10.1016/j.vaccine.2017.03.103
  89. Kochhar S, Bauwens J, Bonhoeffer J. Safety Assessment of Immunization in Pregnancy. 2017;35(48 Pt A):6469-6471. doi:10.1016/j.vaccine.2017.09.033
  90. Rouse CE, Eckert LO, Babarinsa I, Fay E, Gupta M, Harrison MS, Kawai AT, Kharbanda EO, Kucuku M, Meller L, Mallett Moore T, Subelj M, Kochhar S, Tavares-Da-Silva F. Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. 2017; 35(48 Pt A):6563-6574. doi: 10.1016/j.vaccine.2017.01.047.
  91. Kachikis A, Eckert LO, Walker C, Oteng-Ntim E, Guggilla R, Gupta M, Patwardhan M, Mataya R, Mallett Moore T, Alguacil-Ramos AM, Keech C, Gravett M, Murphy H, Kochhar S, Chescheir N. Gestational diabetes mellitus: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 2017; 35(48 Pt A):6555-6562. doi: 10.1016/j.vaccine.2017.01.043.
  92. Easter SR, Eckert LO, Boghossian N, Spencer R, Oteng-Ntim E, Ioannou C, Patwardhan M, Harrison MS, Khalil A, Gravett M, Goldenberg R, McKelvey A, Gupta M, Pool V, Robson SC, Joshi J, Kochhar S, McElrath T.Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 2017; 35(48 Pt A):6546-6554. doi: 10.1016/j.vaccine.2017.01.042.
  93. Boatin AA, Eckert LO, Boulvain M, Grotegut C, Fisher BM, King J, Berg M, Adanu RMK, Reddy U, Waugh JJS, Gupta M, Kochhar S, Kenyon. Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 2017; 35(48 Pt A):6538-6545. doi: 10.1016/j.vaccine.2017.01.050.
  94. Prabhu M, Eckert LO, Belfort M, Babarinsa I, Ananth CV, Silver RM, Stringer E, Meller L, King J, Hayman R, Kochhar S, Riley L. Antenatal bleeding: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. 2017; 35(48 Pt A):6529-6537. doi: 10.1016/j.vaccine.2017.01.081.
  95. Schlaudecker EP, Munoz FM, Bardají A, Boghossian NS, Khalil A, Mousa H, Nesin M, Nisar MI, Pool V, Spiegel HML, Tapia MD, Kochhar S, Black S. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. 2017; 35(48 Pt A):6518-6528. doi: 10.1016/j.vaccine.2017.01.040.
  96. Sweet LR, Keech C, Klein NP, Marshall HS, Tagbo BN, Quine D, Kaur P, Tikhonov I, Nisar MI, Kochhar S, Muñoz FM. Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. 2017; 35(48 Pt A):6506-6517. doi: 10.1016/j.vaccine.2017.01.046.
  97. Sell E, Munoz FM, Soe A, Wiznitzer M, Heath PT, Clarke ED, Spiegel H, Sawlwin D, Šubelj M, Tikhonov I, Mohammad K, Kochhar S. Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. 2017;35(48 Pt A):6501-6505. doi: 10.1016/j.vaccine.2017.01.045.
  98. Cutland CL, Lackritz EM, Mallett-Moore T, Bardají A, Chandrasekaran R, Lahariya C, Nisar MI, Tapia MD, Pathirana J, Kochhar S, Muñoz FM. Low birth weight: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. 2017; 35(48 Pt A):6492-6500. doi: 10.1016/j.vaccine.2017.01.049.
  99. Ross E, Munoz FM, Edem B, Nan C, Jehan F, Quinn J, Mallett Moore T, Sesay S, Spiegel H, Fortuna L, Kochhar S, Buttery J. Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. 2017; 35(48 Pt A):6483-6491. doi: 10.1016/j.vaccine.2017.01.051.
  100. DeSilva M, Munoz FM, Sell E, Marshall H, Tse Kawai A, Kachikis A, Heath P, Klein NP, Oleske JM, Jehan F, Spiegel H, Nesin M, Tagbo BN, Shrestha A, Cutland CL, Eckert LO, Kochhar S, Bardají A. Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. 2017; 35(48 Pt A):6472-6482. doi: 10.1016/j.vaccine.2017.01.044.
  101. Jones CE, Munoz FM, Spiegel HM, Heininger U, Zuber PL, Edwards KM, Lambach P, Neels P, Kohl KS, Gidudu J, Hirschfeld S, Oleske JM, Khuri-Bulos N, Bauwens J, Eckert LO, Kochhar S, Bonhoeffer J.Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. 2016;34(49):5998-6006. doi: 10.1016/j.vaccine.2016.07.032
  102. Jones CE, Munoz FM, Kochhar S, Vergnano S, Cutland CL, Steinhoff M, Black S, Heininger U, Bonhoeffer J, Heath PT. Guidance for collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. 2016; 34(49):6007-6014. doi: 10.1016/j.vaccine.2016.07.007
  103. Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT.Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.  2016;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071.
  104. Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT.Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.  2016; 34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015
  105. Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, Chandler R, Girolomoni G, Hadden RD, Kochhar S, Kucuku M, Monaco G, Ozen S, Pahud B, Phuong L, Bachtiar NS, Teeba A, Top K, Varricchio F, Wise RP, Zanoni G, Živkovic S, Bonhoeffer J. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. 2016;34(51):6634-6640. doi: 10.1016/j.vaccine.2015.09.027.
  106. Holt D, Bouder F, Elemuwa C, Gaedicke G, Khamesipour A, Kisler B, Kochhar S, Kutalek R, Maurer W, Obermeier P, Seeber L, Trusko B, Gould S, Rath B. The importance of the patient voice in vaccination and vaccine safety-are we listening? Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S146-S153. doi: 10.1016/j.cmi.2016.09.027
  107. Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, Honrado Á, Heininger U, Muñoz FM, Eckert L, Steinhoff M, Black S, Padula M, Sturkenboom M, Buttery J, Pless R, Zuber P. Global alignment of immunization safety assessment in pregnancy – The GAIA project. 2016 Dec 1;34(49):5993-5997. doi: 10.1016/j.vaccine.2016.07.006
  108. Pathirana J, Muñoz FM, Abbing-Karahagopian V, Bhat N, Harris T, Kapoor A, Keene DL, Mangili A, Padula MA, Pande SL, Pool V, Pourmalek F, Varricchio F, Kochhar S, Cutland CL. Neonatal Infections: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data. 2016;34(49):6027-6037. doi: 10.1016/j.vaccine.2016.03.040
  109. DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, Joshi J, Oneko M, Rose AE, Dolk H, Trotta F, Spiegel H, Tomczyk S, Shrestha A, Kochhar S, Kharbanda EO.Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.  2016; 34(49):6015-6026. doi: 10.1016/j.vaccine.2016.03.047
  110. Gravett C, Eckert LO, Gravett MG, Dudley DJ, Stringer EM, Mujobu TB, Lyabis O, Kochhar S, Swamy GK.Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.  2016;34(49):6084-6092. doi: 10.1016/j.vaccine.2016.03.043
  111. Pathirana J, Muñoz FM, Abbing-Karahagopian V, Bhat N, Harris T, Kapoor A, Keene DL, Mangili A, Padula MA, Pande SL, Pool V, Pourmalek F, Varricchio F, Kochhar S, Cutland CL.Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.  2016 Dec 1;34(49):6027-6037. doi: 10.1016/j.vaccine.2016.03.040
  112. Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, Nunes T, Pye S, Watson W, Ramos AA, Cordero JF, Huang WT, Kochhar S, Buttery J. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. 2016; 34(49):6047-6056. doi: 10.1016/j.vaccine.2016.03.045
  113. Kerr R, Eckert LO, Winikoff B, Durocher J, Meher S, Fawcus S, Mundle S, Mol B, Arulkumaran S, Khan K, Wandwabwa J, Kochhar S, Weeks A. Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. 2016;34(49):6102-6109. doi: 10.1016/j.vaccine.2016.03.039
  114. Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S, Bhange S, Tila M, Harper DM, Woods C, Kawai AT, Kochhar S, Munoz FM.Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data.  2016;34(49):6057-6068. doi: 10.1016/j.vaccine.2016.03.044
  115. Rouse CE, Eckert LO, Wylie BJ, Lyell DJ, Jeyabalan A, Kochhar S, McElrath TF.Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data.  V 2016 Dec 1;34(49):6069-6076. doi: 10.1016/j.vaccine.2016.03.038.
  116. Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, Nunes AP, Lazo S, Moore TM, Watson W, Kochhar S, Goldenberg RL. Pathways to Preterm Birth: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of immunization Safety Data. Vaccine, 2016; 34(49):6093-6101. doi: 10.1016/j.vaccine.2016.03.054.
  117. Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. 2016; 34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015.
  118. DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, Joshi J, Oneko M, Rose AE, Dolk H, Trotta F, Spiegel H, Tomczyk S, Shrestha A, Kochhar S, Kharbanda EO. Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. 2016; 34(49):6015-6026. doi: 10.1016/j.vaccine.2016.03.047.
  119. Patwardhan M, Eckert LO, Spiegel H, Pourmalek F, Cutland C, Kochhar S, Gonik B. Maternal death: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(49):6077-6083. doi: 10.1016/j.vaccine.2016.03.042.
  120. Jamil KM, Haque R, Rahman R, Faiz MA, Bhuiyan AT, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan MA, Khan MM, Ghosh RS. Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118. doi: 10.1371/journal.pntd.0004118.
  121. Elemuwa C, Kutalek R, Ali M, Mworozi E, Kochhar S, Rath B. Global lessons from Nigeria’s ebolavirus control strategy. Expert Rev Vaccines. 2015;14(11):1397-400. doi: 10.1586/14760584.2015.1064313
  122. Kochhar S. Communicating Vaccine Safety during the development and introduction of vaccines. Curr Drug Saf. 2015;10(1):55-9. doi: 10.2174/157488631001150407110435. PMID: 25859676.
  123. Schwertschlag U, Kumar A,  Kochhar S, Ings R,  Ji Y, de Hostos EL, Choy R, Salam M, Khan WA, Lin P. Pharmacokinetics and Tolerability of iOWH032, an Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel, in Normal Volunteers and Cholera Patients.   146, 5, Suppl 1, S-663, 2014
  124. Maurer W, Seeber L, Rundblad G, Kochhar S, Trusko B, Kisler B, Kush R, Rath B. Standardization and Simplification of Vaccination Records. Expert Rev Vaccines. 2014 Apr;13(4):545-59. doi: 10.1586/14760584.2014.892833
  125. Kochhar S, Rath B, Seeber LD, Rundblad G, Khamesipour A, Ali M. Introducing new vaccines in developing countries. Expert Review of Vaccines.12 (12), 1465-1478, 2013. doi: 10.1586/14760584.2013.855612
  126. Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO. Impact, Challenges and Future Projections for Vaccine Trials in Africa. Am J Trop Med Hyg. 2013; 88(3):414-9. doi: 10.4269/ajtmh
  127. Kochhar S. Challenges and Impact of Conducting Vaccine Trials in Asia and Africa. Hum Vaccin Immunother. 2013; 9(4):924-7. doi: 10.4161/hv.23405
  128. Kochhar S. Scientific Challenges and Opportunities in Developing Novel Vaccines for the Emerging and Developing Markets. Hum Vaccin Immunother. 2013; 9(4):928-31. doi: 10.4161/hv.23514
  129. Bonhoeffer J, Imoukhuede EB, Aldrovandi G, Bachtiar NS, Chan ES, Chang S, Chen RT, Fernandopulle R, Goldenthal KL, Heffelfinger JD, Hossain S, Jevaji I, Khamesipour A, Kochhar S, Makhene M, Malkin E, Nalin D, Prevots R, Ramasamy R, Sellers S, Vekemans J, Walker KB, Wilson P, Wong V, Zaman K, Heininger U. Template Protocol for Clinical Trials investigating Vaccines- Focus on Safety Elements. 2013;31(47):5602-20. doi: 10.1016/j.vaccine.2013.02.041
  130. Rath B, Ali M, Elemuwa C, Maurer W, Bouder F, Mworozi E, Diedrich S, Khamesipour A, Chitwood I, Kochhar S. Prioritizing Polio. Expert Rev Vaccines. 2012;11(12):1389-92. doi: 10.1586/erv.12.128
  131. Muehlhans S, Richard G, Ali M, Codarini G, Elemuwa C, Khamesipour A, Maurer W, Mworozi E, Kochhar S, Rundblad G, Vuitton D, Rath B. Safety Reporting in Developing Country Vaccine Clinical Trials- A Systematic Review. 2012; 30(22):3255-65. doi: 10.1016/j.vaccine.2012.02.059
  132. Rath B, Ali M, Codarini G, Elemuwa C, Khamesipour A, Maurer W, Mworozi E, Rundblad G, Varughese S, Kochhar S. Promoting Evidence-Based Vaccine Safety Research and Communication. J Trop Pediatr. 2012;58(3):167-9. doi: 10.1093/tropej/fms022
  133. Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD.Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: A Phase I trial in HIV-uninfected Indian volunteers.PLoS One. 2013; 8(2):e55831. doi: 10.1371/journal.pone.0055831
  134. Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother. 2012; 8(5):630-8. doi: 10.4161/hv.19454.
  135. Mehendale S, Sahay S, Thakar M, Sahasrabuddhe S, Kakade M, Shete A, Shrotri A, Spentzou A, Tarragona T, Stevens G, Kochhar S, Excler JL, Fast P, Paranjape R. Safety and Immunogenicity of tgAAC09, a recombinant Adeno-Associated Virus Type 2 HIV-1 subtype C vaccine in India. Indian J Med Res. 2010; 132:168-75
  136. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant
    HIV-1 Subtype C Modified Vaccinia Ankara Virus Vaccine. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.
  137. Kochhar S, Excler JL, Fast P. Care and treatment for volunteers in IAVI-sponsored HIV vaccine clinical trials in India. Retrovirology 6(Suppl 3), P189 (2009). https://doi.org/10.1186/1742-4690-6-S3-P189
  138. Schmidt C, Kochhar S, Excler JL, Smith C, McMichael A, Bwayo J, Jaoko WG, Weber J, Kaleebu P, Peters B, Pantaleo G, Vardas E, Robinson A, Ho D, Keefer M, Ramanathan VD, Boyle R, Fast P. Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates based on Modified Vaccinia Anara (MVA). AIDS Research and Human Retroviuses. 24: 106-107, 2008
  139. Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE. A Phase 1 Study to evaluate the safety and immunogenicity of a recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. AIDS Res Hum Retroviruses. 2008 Jun;24(6):873-80. doi: 10.1089/aid.2007.0292
  140. Excler JL, Kochhar S, Kapoor S, Das S, Bahri J, Ghosh MD, Ganguly NK, Nayyar A, Chataway M. Preparedness for AIDS Vaccine Trials in India. Indian J Med Res. 2008 Jun;127(6):531-8
  141. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant Modified Vaccinia Ankara Virus (TBC-M4) multigenic HIV subtype C Vaccine. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.
  142. Kochhar S, Excler JL. Advancement in AIDS Vaccine development. Journal of Immunology and Immunopathology, 8(2):85-92, Dec. 2006.
  143. Aggarwal KK, Kochhar S. An 80-year-old male with Atrial Fibrillation- To Anticoagulate or not – Current Concepts. Indian Journal of Clinical Pharmacology, 14(1):42. 2003
  144. Aggarwal KK, Kochhar S. Osteoporotic male with a repeat dexa bone densitometry. Indian Journal of Clinical Pharmacology; 14(3):45. 2003